MARINUS PHARMAC. DL-001
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations i… Read more
MARINUS PHARMAC. DL-001 (61Y) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MARINUS PHARMAC. DL-001 (61Y) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MARINUS PHARMAC. DL-001 - Net Assets Trend (None–None)
This chart illustrates how MARINUS PHARMAC. DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MARINUS PHARMAC. DL-001 (None–None)
The table below shows the annual net assets of MARINUS PHARMAC. DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MARINUS PHARMAC. DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MARINUS PHARMAC. DL-001 Competitors by Market Cap
The table below lists competitors of MARINUS PHARMAC. DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AVALON ADV. MAT. INC.
F:OU5A
|
$19.96 Million |
|
PJ Metal Co. Ltd
KQ:128660
|
$19.96 Million |
|
ITALIAN SEA GROUP
F:6QN
|
$19.96 Million |
|
Rio Paranapanema Energia S.A
SA:GEPA3
|
$19.96 Million |
|
Rushil Decor Limited
NSE:RUSHIL
|
$19.96 Million |
|
DeepMarkit Corp.
NASDAQ:MKTSF
|
$19.95 Million |
|
MWB0
XETRA:MWB0
|
$19.95 Million |
|
Myomo Inc
NYSE MKT:MYO
|
$19.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MARINUS PHARMAC. DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MARINUS PHARMAC. DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MARINUS PHARMAC. DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MARINUS PHARMAC. DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MARINUS PHARMAC. DL-001 (61Y) | €- | N/A | N/A | $19.96 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |